Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
51 hedge funds and large institutions have $127M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 1 closing their positions.
2,300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 1
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
82% more funds holding
Funds holding: 28 → 51 (+23)
81% more capital invested
Capital invested by funds: $70M → $127M (+$56.5M)
25.56% more ownership
Funds ownership: 31.33% → 56.89% (+26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
+$6.6M |
| 2 |
SCM
Saba Capital Management
New York
|
+$5.73M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$5M |
| 4 |
DCM
DG Capital Management
New York
|
+$4.37M |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingstown Capital Management
New York
|
-$2.92M |
| 2 |
TCM
Tenor Capital Management
New York
|
-$1.33M |
BIOT Hedge Fund Activity: Q2 2021 in Review
51 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q2 2021, worth a combined $127M — up 81% from $70M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BIOT positions and 1 closed out — a net gain of 23 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was Linden Advisors, opening a new position worth an estimated $6.6M. The largest seller was Kingstown Capital Management, exiting entirely with an estimated $2.92M sold.
- 51 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q2 2021, up from 28 in Q1 2021.
- Funds reported $127M of Biotech Acquisition Company Class A Ordinary Shares stock for Q2 2021, up 81% quarter-over-quarter.
- 24 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q2 2021 and 1 closed out, a net change of +23 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q2 2021 was Linden Advisors, an estimated $6.6M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q2 2021 was Kingstown Capital Management, an estimated $2.92M sold.
Based on aggregated 13F filings for Q2 2021.